2024 ASCCP Scientific Meeting on Anogenital and HPV-Related Diseases
Through an array of educational offerings, the 2024 ASCCP Scientific Meeting on Anogenital and HPV-Related Diseases will bring together healthcare professionals from different backgrounds and experience levels who are interested in staying informed about the latest research dedicated to improving clinical outcomes and to reducing the burden of anogenital and HPV-related diseases around the world.
Educational Objectives:
- Integrate into practice new insights from the latest research on prevention, diagnosis and management of anogenital and HPV-related diseases.
- Describe the biology, epidemiology, natural history, and immune response to HPV, as well as the societal costs associated with HPV infections.
- Apply consensus guidelines for cervical cancer screening and management of cervical abnormalities to the general population as well as those in special circumstances.
- Apply novel screening and management strategies to underserved and under-screened individuals (transgender, incarcerated, etc.).
- Apply colposcopy to the diagnosis and management of anogenital and HPV-related diseases in ways that reflect its usefulness and maximum benefits while minimizing potential harms.
- Diagnose and treat HPV-related diseases including those that affect the cervix, vagina, vulva, anus, and head/neck. .
- Identify strategies for prevention and screening of HPV-associated oropharyngeal disorders.
- Identify novel and experimental uses of therapeutic and prophylactic HPV vaccines, including the use of “catch-up” HPV immunization.
- Apply HPV testing and relevant diagnostic tests to clinical practice in a directed, evidence-based, cost-effective manner.
- Describe the vaginal microbiome and describe its impact on HPV clearance.
- Recognize the impact of implicit bias on patient care and learn techniques to identify and address this bias.
- Apply data on HPV ecology to screening and management of patients who are postmenopausal.
- Manage positive cytology and HPV test results, high risk HPV genotype results, and histologically confirmed anogenital neoplasia, reflecting current and future patient risk of high grade neoplasia.
Continuing Medical Education (CME)
ACCME Accreditation Statement
ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide medical education for physicians.
Credit Designation Statement
The American Society for Colposcopy and Cervical Pathology (ASCCP) designates this Other Activity (Live and Enduring Material) for a maximum of 28.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures
All those who have an opportunity to control or influence content (Faculty, Program Directors, Reviewers, Staff, etc), are required to complete a disclosure form based on the following instructions:
ASCCP members and the general public place great trust in the work of the Society. Real or perceived undisclosed conflicts of interest may jeopardize that trust and ASCCP’s effectiveness. Conflicts of interest also may affect the objectivity of decisions that ASCCP officers and volunteers make. To minimize the potential impact of possible conflicts of interest, the Board of Directors has determined that all participants in ASCCP activities must report all real or potential conflicts prior to the activity being developed and delivered to the learners.
Additionally, the ACCME Standards for Integrity and Independence require that we disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education.
Please disclose all financial relationships that you have had in the past 24 months with ineligible companies (see definition below). For each financial relationship, enter the name of the ineligible company and the nature of the financial relationship(s). There is no minimum financial threshold; we ask that you disclose all financial relationships, regardless of the amount, with ineligible companies. You should disclose all financial relationships regardless of the potential relevance of each relationship to the education.
An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit accme.org/standards.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to ASCCP any financial relationship(s) that have occurred within the prior 24 months with any ineligible companies. Financial relationships are defined as remuneration in any amount from ineligible companies in the form of grants, research support, consulting fees, salary, ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds), honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors, or other financial benefits. The intent of this disclosure is not to prevent individuals with financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. ASCCP has reviewed all disclosures and mitigated all relevant financial relationships that have been identified.
The following person(s) disclosed financial relationships:
Patty Cason, MS, FNP-BC – Faculty – Merck (Speaker, Honorarium) - Sebela Women's Health (Trainer, consultant) - Organon (Nexplanon trainer) – Evofem (Consultant: last contact October 2020)
Philip E. Castle, PhD, MPH – Faculty - Roche - BD Diagnostics - Arbor Vita (Received HPV tests and assays for research at a reduced or no cost from Roche, BD, Cepheid, and Arbor Vita Corporation)
Christine Conageski, MD, MSc – Faculty – Content Reviewer - Pfizer (I am the co-PI on an RSV vaccine study in pregnant women. I receive no direct funds, but Pfizer sends money to my institution on my behalf to support our research team.)
Teresa Darragh, MD – Faculty – Pfizer, Inovio, AstraZeneca, PDS Biotechnologies, BD Diagnostics (Grant Recipient, Funding)
Levi S. Downs Jr., MD, MS – Faculty, Moderator – Aspira Women's Health (Consultant, Honorarium)
Linda Eckert, MD – Faculty - I am the author of a book entitled "Enough: Because We Can Stop Cervical Cancer" that will be published January 11, 2024 by Cambridge University Press. I do not deem this a commercial conflict of interest, but I am actively speaking about cervical cancer.
Mark H. Einstein, MD, MS – Faculty – Papivax (Consultant) – Merck (Consultant) - BD Diagnostics (Consultant) - PDS Biotechnologies (Consultant)
Andrew T. Goldstein, MD - Content Reviewer - Daré Bioscience (Employee, Salary) - AbbVie (Advisory Board, Honorarium) - Incyte (Consultant, Honorarium) - The Gynecologic Cancers Research Foundation (Executive Board/Board of Directors, Travel)
Richard S. Guido, MD – Faculty - ASCCP (Consultant, Funding), Myovant Pharmaceuticals (Advisory Board, Honorarium), Inovio (Consultant, Funding)
Hope K. Haefner, MD – Faculty – UptoDate (Royalty)
Warner K. Huh, MD – Faculty – Roche (Consultant, Honorarium)
Kathy MacLaughlin, MD – Faculty - Mayo Clinic (Funding)
Jenna Marcus, MD – Faculty - Content Reviewer - Speaker's Bureau (Consultant, Honorarium)
Stewart Massad, MD - Faculty - Merck (Consultant, Honorarium)
Anna-Barbara Moscicki, MD – Faculty – Merck (Advisory Board, Honorarium)
Amber Naresh, MD - Content Reviewer – Merck (Funding, Employee, Salary)
Akiva Novetsky, MD, MS - Faculty - Roche (Consultant, Funding)
Lisa Rahangdale, MD, MPH – Faculty – Merck (Grant Recipient, Funding) – Antiva (Consultant)
Sangini S. Sheth, MD, MPH, FACOG – Faculty – Merck (Consultant, Honorarium)
Elizabeth Stier, MD – Faculty – Inovio (Funding)
Colleen K. Stockdale, MD, MS – Faculty - JLGTD (Associate Editor, Honorarium)
All of the financial relationships listed for these individuals have been mitigated.
The following person(s) disclosed no financial relationships:
Andreia Alberquerque, MD, PhD - Faculty – Online Sessions: 2023 Best Paper and Top (3) Articles
Meredith Alston, MD - Content Reviewer
Jacob Bornstein, MD, MPA – Faculty – Online Sessions: 2023 Best Paper and Top (3) Articles
Matthys Botha, MD - Faculty – Online Sessions: 2023 Best Paper and Top (3) Articles
Swati Bhardwaj, MD - Content Reviewer
Lance Bruck, MD - Content Reviewer
Zhao Chao, MD – Faculty
David P. Chelmow, MD – Faculty, Moderator
Mingyang Chen - Faculty
Victor M. Feldbaum, MD - Content Reviewer
Sarah Feldman, MD, MPH - Faculty
Lisa Flowers, MD, MPH - Faculty
Lisa R. Gabor, MD - Faculty
Francisco Garcia, MD, MPH - Faculty
Patti E. Gravitt, PhD, MS - Faculty
Stephanie Hamby, FNP, NP, RN, WHNP, NCMP - Content Reviewer
Ashley Jennings, MD - Content Reviewer
Xuezhi (Daniel) Jiang, MD, PhD, MSc - Content Reviewer
Kelsey Kelso, MD - Content Reviewer
Michelle J. Khan, MD, MPH - Faculty
Rachel Kupets, MD, MSc - Content Reviewer
Mauricio Maza, MD, MPH - Faculty
Shane Mudrinich, MD - Faculty
Chemtai Mungo, MD, MPH - Faculty
Erin L. Nelson, MD - Faculty
Esteban Ortega, MD, MPH - Content Reviewer
Susan K. Park, MD, MPH - Content Reviewer
Rebecca Perkins, MD, MSc - Faculty
Marta Preston, BBiomed, MD - Faculty – Online Sessions: 2023 Best Paper and Top (3) Articles
Megha Ramaswamy, PhD, MPH - Faculty
Vikrant Sahasrabuddhe, MPH, MBBS, DrPH - Faculty
Mila M. B. Pontremoli Salcedo, MD, PhD - Faculty
Debbie Saslow, PhD - Faculty
Kelsey C. Schmidt, MD - Faculty
Peter F. Schnatz, DO, MBA, FACOG, FACP, NCMP – Faculty
Alan G. Waxman, MD, MPH - Faculty, Moderator
Nicolas Wentzensen, MD, PhD - Faculty
Gabrielle Whitmore, MD, MBS - Faculty
Amy Wiser, MD – Faculty – Content Reviewer
Joe Pymm – Staff
Kerry Curtis — Staff
Liesl Robinson — Staff
Diane Catalano – Staff
Grant Supporters
This program is supported by independent educational grants from Abbott Laboratories and Merck Sharp & Dohme LLC